Intellia Therapeutics (NTLA) 2026 investment analysis: in-vivo CRISPR gene editing differentiation, the NTLA-2001 ATTR amyloidosis and NTLA-2002 hereditary angioedema late-stage trials, cash burn and dilution, regulatory and safety risk, plus bull and bear scenarios for investors.
RXRX (Recursion Pharmaceuticals) 2026 stock outlook. A qualitative deep dive into the AI drug discovery platform Recursion OS, the BioHive supercomputer, Nvidia's investment and exascale compute, the clinical pipeline, big-pharma partnerships, heavy cash burn, the Exscientia merger, and dilution risk.
Análisis de HLB (KOSDAQ 028300) 2026: la terapia combinada de rivoceranib contra el cáncer de hígado y el único catalizador de aprobación de la FDA, riesgo de CRL/fabricación/socio, la compleja estructura de filiales del grupo HLB, la volatilidad impulsada por minoristas, y en qué se diferencia una biotech coreana en fase clínica de Celltrion, Samsung Biologics y Alteogen.
SK Bioscience (KRX: 302440) 2026 stock analysis: own vaccine pipeline (pneumococcal, shingles, flu), the pivot from one-off COVID manufacturing into recurring CDMO and cell-and-gene therapy contract production, German acquisition and glocalization strategy, plus the post-COVID earnings cliff and R&D-burn risks.
HLB (KOSDAQ 028300) 2026 stock analysis: rivoceranib liver-cancer combination therapy and the single US FDA approval catalyst, CRL/manufacturing/partner risk, the complex HLB Group affiliate structure, retail-driven volatility, and how a clinical-stage Korean biotech binary differs from Celltrion, Samsung Biologics, and Alteogen.
Alnylam Pharmaceuticals (ALNY) stock outlook 2026. A qualitative look at the RNAi/siRNA platform, the four-product commercial franchise, the Amvuttra opportunity in ATTR cardiomyopathy versus Pfizer's tafamidis and BridgeBio's acoramidis, the Novartis/Roche/Regeneron royalty model, nucresiran's late-stage trials, and the path to sustained profitability.